thymalfasin

isolated from thymus gland; octaeicosapeptide; one of the polypeptides of thymosin fraction V; see also record for thymosin fraction V; FDA approved orphan drug status for malignant melanoma although mechanism uncertain

Also Known As:

Networked: 181 relevant articles (33 outcomes, 46 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Garaci, Enrico: 6 articles (10/2012 - 08/2003)
2.	Romani, Luigina: 5 articles (04/2010 - 10/2006)
3.	Rasi, Guido: 5 articles (11/2007 - 08/2003)
4.	Bozza, Silvia: 4 articles (04/2010 - 10/2006)
5.	Bonifazi, Pierluigi: 4 articles (04/2010 - 10/2006)
6.	Bistoni, Francesco: 4 articles (11/2007 - 10/2006)
7.	Shen, Feng: 3 articles (01/2015 - 05/2004)
8.	Tuthill, Cynthia: 3 articles (01/2015 - 06/2005)
9.	Li, Ning: 3 articles (04/2014 - 11/2004)
10.	Pierimarchi, Pasquale: 3 articles (10/2012 - 08/2003)

Related Diseases

1.	Chronic Hepatitis B 09/01/1999 - "Previous clinical trials have suggested that thymosin alpha1 (Talpha1), an immunomodulatory peptide, may be effective in the treatment of chronic hepatitis B (CHB). " 01/01/1999 - "Thymosin alpha1, an immunomodulatory endogenous peptide, has been shown to be effective in the treatment of chronic hepatitis B and C. " 05/01/1998 - "Thymosin alpha1 (Talpha) is an immune modifier that has been shown in a pilot study to be effective for chronic hepatitis B; this requires confirmation. " 10/01/2003 - "The efficacy of thymosin alpha 1 (Talpha1) in patients with chronic hepatitis B still requires confirmation. " 05/01/1998 - "Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial."
2.	Neoplasms (Cancer) 01/01/2015 - "Combination of thymalfasin significantly improved survival and prolonged the time to tumor recurrence in patients who received transcatheter arterial chemoembolization after tumor resection. " 08/01/2003 - "Treatment of thymosin alpha 1 increased the number of CD4 cells and improved the NK activity, and also improved the quality of life of the elderly patients with malignant tumor. " 05/01/1985 - "Thymosin alpha 1, in vitro, was associated with improvement in LMI in the cancer patients. " 01/01/1999 - "Thymosin alpha1 kinetics from this study are comparable to those previously obtained in Japanese volunteers or cancer patients, but may be influenced by the drug formulation used." 10/01/2015 - "Thymosin alpha 1 (Tα1) is commonly used for treating several diseases; however its usage has been limited because of poor penetration of the target tissue, such as tumor cells. "
3.	Sepsis (Septicemia) 01/01/2013 - "The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial." 01/01/2009 - "[Evaluation of efficacy of thymosin alpha1 in the treatment of sepsis: a systematic review]." 01/01/2013 - "In light of the crucial role of immunologic derangement in severe sepsis, thymosin alpha 1 (Tα1) is considered as a promising beneficial immunomodulatory drug. " 03/01/2009 - "CBP and thymosin alpha1 could increase cellular immunity in patients with severe sepsis, promote recovery of organ function and improve prognosis. " 03/01/2009 - "To discuss the effect of continuous blood purification (CBP), thymosin alpha1 and combined therapy on cellular immunity in patients with severe sepsis. "
4.	Infection 08/14/2009 - "Thymosin alpha 1 (Talpha1) is a naturally occurring thymic peptide and has previously been shown to be a potential therapy for some immunodeficiencies, malignancies, and infections. " 10/01/2008 - "Thymalfasin has shown efficacy in the treatment of chronic HCV infection. " 11/01/2007 - "Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide, is approved for treatment of some viral infections and as an immune adjuvant. " 09/01/2007 - "Thymosin alpha1 (Talpha1), first described and characterized by Allan Goldstein in 1972, is used worldwide for the treatment of some immunodeficiencies, malignancies, and infections. " 05/01/2002 - "SciClone developed and launched Talpha1, under the trade name Zadaxin, for the treatment of HBV and hepatitis C virus (HCV) infections. "
5.	Chronic Hepatitis C 06/01/1996 - "A randomized, double-blind, placebo-controlled trial was performed to evaluate the efficacy and safety of thymosin alpha 1 (alpha 1) in treating chronic hepatitis C. " 06/01/1996 - "A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C." 04/01/2010 - "Immunological modifications during treatment with thymosin alpha1 plus antiviral therapy in chronic hepatitis C." 06/01/2007 - "Thymosin alpha 1 is a polypeptide with immunomodulatory properties that has been suggested to increase response rates in patients with chronic hepatitis C. " 11/01/2004 - "Thymosin alpha 1 (Ta-1) is a polypeptide with immunomodulatory properties that has been suggested to increase response rates in patients with chronic hepatitis C. "

Related Drugs and Biologics

1.	Interferon-alpha (Interferon Alfa)
2.	Interferons
3.	urinastatin (MR 20)
4.	Ribavirin (Virazole)
5.	thymosin fraction 5
6.	thymalfasin
7.	Interleukin-2 (IL2)
8.	Cyclophosphamide (Cytoxan)
9.	Lamivudine (3TC)
10.	Vaccines

Related Therapies and Procedures

1.	Immunomodulation
2.	Immunotherapy
3.	Transplants (Transplant)
4.	Drug Therapy (Chemotherapy)
5.	Retreatment